Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: Results from a randomized clinical trial

Leukemia Research

Volumn 37, Issue 3, 2013, Pages 259-265

  Revicki, Dennis A ^a   Brandenburg, Nancy A ^b   Muus, Petra ^c   Yu, Ren ^a   Knight, Robert ^b   Fenaux, Pierre ^d  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b CELGENE CORPORATION   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d AVICENNE HOSPITAL   (France)

Author keywords

Anemia; Clinical trial; Health related quality of life; Myelodysplastic syndrome

Indexed keywords

HEMOGLOBIN; LENALIDOMIDE; PLACEBO;

ADULT; AGED; ANALYSIS OF COVARIANCE; ARTICLE; CHROMOSOME 9; CHROMOSOME DELETION; CONTROLLED STUDY; CYTOGENETICS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; ERYTHROID CELL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, MACROCYTIC; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; COMBINED MODALITY THERAPY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PLACEBOS; QUALITY OF LIFE; RISK; SEVERITY OF ILLNESS INDEX; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84872927737     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.11.017     Document Type: Article

References (27)

1. Hellstrom-Lindberg E. Approach to anemia associated with myelodysplastic syndromes. Curr Hematol Rep 2003, 2(March (2)):122-129.
2. Kornblith A.B., Herndon J.E.2nd, Silverman L.R., et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a cancer and leukemia group B study. J Clin Oncol 2002, 20(May (10)):2441-2452.
3. Sobrero A., Puglisi F., Guglielmi A., et al. Fatigue: a main component of anemia symptomatology. Semin Oncol 2001, 28(April (2 Suppl. 8)):15-18.
4. Greenberg P.L., Attar E., Bennett J.M., et al. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw 2011, 9(January (1)):30-56.
5. Caocci G., La Nasa G., Efficace F. Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes. Expert Rev Hematol 2009, 2(February (1)):69-80.
6. Balleari E., Rossi E., Clavio M., et al. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol 2006, 85(March (3)):174-180.
7. Casadevall N., Durieux P., Dubois S., et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004, 104(July (2)):321-327.
8. Gabrilove J., Paquette R., Lyons R.M., et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 2008, 142(July (3)):379-393.
9. Giagounidis A.A., Haase S., Germing U., et al. Treatment of myelodysplastic syndrome with isolated del (5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study. Ann Hematol 2005, 84(June (6)):389-394.
10. Kantarjian H., Issa J.P., Rosenfeld C.S., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106(April (8)):1794-1803.
11. Pinchon D.J., Stanworth S.J., Doree C., Brunskill S., Norfolk D.R. Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review. Am J Hematol 2009, 84(October (10)):671-677.
12. Spiriti M.A., Latagliata R., Niscola P., et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 2005, 84(March (3)):167-176.
13. Stasi R., Abruzzese E., Lanzetta G., Terzoli E., Amadori S. Darbepoetin alfa for the treatment of anemic patients with Low- and Intermediate-1-risk myelodysplastic syndromes. Ann Oncol 2005, 16(December (12)):1921-1927.
14. Lubbert M., Suciu S., Baila L., et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011, 29(May (15)):1987-1996.
15. Eisenmann K.M., Dykema K.J., Matheson S.F., et al. 5q-Myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics. Oncogene 2009, 28(October (39)):3429-3441.
16. Heise C., Carter T., Schafer P., Chopra R. Pleiotropic mechanisms of action of lenalidomide efficacy in del (5q) myelodysplastic syndromes. Expert Rev Anticancer Ther 2010, 10(October (10)):1663-1672.
17. Kotla V., Goel S., Nischal S., et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009, 2:36.
18. Pellagatti A., Jadersten M., Forsblom A.M., et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA 2007, 104(July (27)):11406-11411.
19. Quach H., Ritchie D., Stewart A.K., et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010, 24(January (1)):22-32.
20. Fenaux P., Giagounidis A., Selleslag D., et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011, 118(October (14)):3765-3776.
21. Cheson B.D., Bennett J.M., Kantarjian H., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96(December (12)):3671-3674.
22. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108(July (2)):419-425.
23. Cella D., Eton D.T., Lai J.S., Peterman A.H., Merkel D.E. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002, 24(December (6)):547-561.
24. Yellen S.B., Cella D.F., Webster K., Blendowski C., Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997, 13(February (2)):63-74.
25. Efficace F., Bottomley A., Osoba D., et al. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials - does HRQOL evaluation in prostate cancer research inform clinical decision making?. J Clin Oncol 2003, 21(September (18)):3502-3511.
26. Hedeker D., Gibbons R. Longitudinal Data Analysis 2006, John Wiley & Sons, Hoboken, NJ.
27. Clavio M., Nobili F., Balleari E., et al. Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report. Eur J Haematol 2004, 72(February (2)):113-120.